Innate Pharma (IPHA) Change in Cash (2019 - 2025)

Innate Pharma (IPHA) has reported Change in Cash for 7 consecutive years, with -$43.6 million the latest figure, recorded in Q4 2025.

• Quarterly Change in Cash fell 810.05% year-over-year to -$43.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$64.6 million (down 81.57% YoY) and the FY2025 annual result came in at -$43.6 million, down 810.05% from the prior year.
• Change in Cash eased to -$43.6 million in Q4 2025 per IPHA's latest filing, from -$4.8 million in the prior quarter.
• Over the last five years, Change in Cash for IPHA reached as high as -$699841.9 in Q2 2024 and fell as low as -$43.6 million in Q4 2025.
• A 5-year average of -$19.7 million and a median of -$15.5 million in 2023 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash surged 97.54% — and 2023, when it sank 1487.48%.
• Year by year, Change in Cash stood at -$37.6 million in 2021, then jumped by 40.88% to -$22.2 million in 2022, then jumped by 30.27% to -$15.5 million in 2023, then jumped by 69.09% to -$4.8 million in 2024, then tumbled by 810.05% to -$43.6 million in 2025.
• According to Business Quant data, Change in Cash over the past three periods registered -$43.6 million, -$4.8 million, and -$699841.9 for Q4 2025, Q4 2024, and Q2 2024 respectively.